Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.35 -4.5%	$2.06	$1.20 ▼ $6.75	$139.88M	2.71	1.57 million shs	6.06 million shs
FATE Fate Therapeutics	$1.04 -5.5%	$1.23	$0.66 ▼ $5.92	$126.06M	2.23	2.22 million shs	3.75 million shs
KYTX Kyverna Therapeutics	$3.28 -5.5%	$2.57	$1.78 ▼ $11.40	$149.97M	2.52	393,657 shs	3.72 million shs
LVTX LAVA Therapeutics	$1.31 +0.4%	$1.30	$0.85 ▼ $2.39	$34.33M	0.48	154,731 shs	11,959 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-4.47%	+0.86%	+18.09%	+45.96%	-49.89%
FATE Fate Therapeutics	-5.45%	-12.61%	-18.11%	+22.45%	-68.10%
KYTX Kyverna Therapeutics	-5.48%	+6.84%	+28.63%	+64.00%	-54.88%
LVTX LAVA Therapeutics	+0.38%	0.00%	-0.76%	+1.55%	-29.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.0208 of 5 stars	3.5	3.0	0.0	3.5	1.7	0.6
FATE Fate Therapeutics	4.139 of 5 stars	3.1	3.0	4.7	2.6	1.7	0.6
KYTX Kyverna Therapeutics	2.4407 of 5 stars	3.6	1.0	0.0	3.3	1.7	0.6
LVTX LAVA Therapeutics	2.2519 of 5 stars	3.0	5.0	0.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.00	Buy	$14.60	521.28% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	268.59% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	464.02% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	141.73% Upside

Current Analyst Ratings Breakdown

Latest LVTX, FATE, KYTX, and BDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/3/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $4.00
4/1/2025	KYTX Kyverna Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $20.00
3/31/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.50

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$1.47 per share	N/A
FATE Fate Therapeutics	$13.63M	8.74	N/A	N/A	$2.80 per share	0.37
KYTX Kyverna Therapeutics	$7.03M	20.17	N/A	N/A	$6.17 per share	0.53
LVTX LAVA Therapeutics	$11.98M	2.88	N/A	N/A	$1.06 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.06	39.17	N/A	N/A	N/A	4.70%	3.47%	8/5/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)

Latest LVTX, FATE, KYTX, and BDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
3/28/2025	Q4 2024	LVTX LAVA Therapeutics	-$0.32	-$0.14	+$0.18	-$0.14	$2.40 million	$2.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	9.24	9.24
FATE Fate Therapeutics	N/A	8.81	8.81
KYTX Kyverna Therapeutics	N/A	7.44	7.44
LVTX LAVA Therapeutics	N/A	6.73	6.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
FATE Fate Therapeutics	97.54%
KYTX Kyverna Therapeutics	18.08%
LVTX LAVA Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
FATE Fate Therapeutics	5.51%
KYTX Kyverna Therapeutics	22.00%
LVTX LAVA Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	53.47 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	33.71 million	Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable

LVTX, FATE, KYTX, and BDTX Headlines

Recent News About These Companies

LAVA Therapeutics Shareholders Approve Key Proposals in Meeting

June 13, 2025 | tipranks.com

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

May 16, 2025 | finance.yahoo.com

LAVA Therapeutics N.V.: LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 15, 2025 | finanznachrichten.de

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 14, 2025 | globenewswire.com

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock News

April 16, 2025 | gurufocus.com

LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency

April 16, 2025 | quiverquant.comQ

LAVA Therapeutics (LVTX) Secures $5.1 Million Debt Waiver from Netherlands Enterprise Agency | ...

April 16, 2025 | gurufocus.com

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

April 16, 2025 | globenewswire.com

Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year

March 29, 2025 | markets.businessinsider.com

LAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99M

March 28, 2025 | seekingalpha.com

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

March 28, 2025 | globenewswire.com

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

February 28, 2025 | benzinga.com

Cautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce Reduction

February 27, 2025 | tipranks.com

Lava Therapeutics announces evaluation of strategic options

February 26, 2025 | markets.businessinsider.com

LAVA Therapeutics (NASDAQ:LVTX) Stock Quotes, Forecast and News Summary

February 26, 2025 | benzinga.com

Lava Therapeutics trims workforce by 30% to preserve cash

February 25, 2025 | bizjournals.com

Serina Therapeutics Appoints Karen J. Wilson to Board of Directors

January 14, 2025 | quiverquant.comQ

LAVA Therapeutics Doses First Patient in Phase 1 Study of Bispecific Gammabody® LAVA-1266 for CD123-Expressing Blood Cancers

January 10, 2025 | quiverquant.comQ

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

January 10, 2025 | globenewswire.com

LAVA Therapeutics to Transition to U.S. Domestic Issuer

January 2, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock
By Leo Miller | June 9, 2025
View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock

LVTX, FATE, KYTX, and BDTX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.35 -0.11 (-4.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.07 (+2.98%)

As of 06/27/2025 07:54 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Fate Therapeutics NASDAQ:FATE

$1.04 -0.06 (-5.45%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.06 +0.01 (+1.44%)

As of 06/27/2025 07:56 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Kyverna Therapeutics NASDAQ:KYTX

$3.28 -0.19 (-5.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.25 -0.03 (-0.91%)

As of 06/27/2025 07:53 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

LAVA Therapeutics NASDAQ:LVTX

$1.31 +0.01 (+0.38%)

Closing price 06/27/2025 03:55 PM Eastern

Extended Trading

$1.32 +0.01 (+0.76%)

As of 06/27/2025 04:04 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time